Clinical trial risks are often discussed at the study level, such as recruitment delays, protocol deviations, or data quality issues. However, risks can also emerge at the portfolio level, affecting multiple studies within a program, or at the global level, where broader geopolitical and economic developments influence the entire research ecosystem.
The COVID-19 pandemic demonstrated how quickly global events can disrupt clinical trial operations. Travel restrictions, site closures, and interruptions to investigational product supply chains forced sponsors to rapidly adapt monitoring approaches, patient management strategies, and data oversight models across hundreds of studies simultaneously.
While traditional risk assessments focus on individual study execution, global developments often create portfolio-level risks affecting multiple trials at once. These risks may emerge from geopolitical developments, regulatory shifts, or disruptions in international logistics that influence entire development programs rather than isolated studies.
Today, the clinical research landscape is increasingly shaped by global events. Regional instability, trade disruptions, shifting regulatory environments, and pressure on supply chains can all impact how trials are planned and executed.
Recent industry analyses illustrate how these dynamics are already affecting the sector. According to an industry analysis of R&D trends, global clinical trial starts declined by around 15% in 2023 compared to 2022, falling significantly below the peak observed in 2021.
At the same time, geopolitical disruptions are increasingly affecting day-to-day trial operations. Global instability can interrupt pharmaceutical supply chains, potentially delaying the shipment of investigational products and complicating international trial logistics.
Real-world events have already demonstrated how fragile trial operations can become in such environments. For example, during the early stages of the conflict in Ukraine, hundreds of clinical studies were affected as sponsors paused recruitment and reassessed trial operations in the region.
However, global disruptions can also reshape research opportunities. In some therapeutic areas, humanitarian crises or regional health emergencies may unfortunately increase the prevalence of certain conditions, creating new research possibilities. A notable example comes from Ukraine, where clinical research teams continued operating despite extreme conditions. Under the leadership of Dr. Yurii Lebid, the Kyiv-based CRO Pharmaxi managed to keep sites operational and help ensure continued patient access to investigational treatments during the conflict. Learn more about this topic in the webinar discussion.
These dynamics illustrate how global developments can simultaneously create operational risk and new complexities across entire clinical portfolios. What may initially appear as an external event can quickly cascade into operational signals affecting site performance, patient access, regulatory timelines, and data integrity across multiple studies.
This is where Risk-Based Quality Management (RBQM) becomes particularly valuable. RBQM frameworks enable organizations to systematically identify, assess, and monitor risks not only within individual studies but also across broader operational contexts. RBQM oversight integrates multiple signals into decision-making — including structured risk assessments, Key Risk Indicators (KRIs), Quality Tolerance Limits (QTLs), and centralized monitoring insights — allowing teams to dynamically adjust oversight strategies and maintain effective control across complex trial ecosystems.
As the complexity of global clinical development continues to grow, organizations are increasingly looking for smarter ways to detect, prioritize, and manage global risks in clinical trials across their studies and portfolios. Modern RBQM technologies and specialized expertise can provide the visibility and structure needed to navigate uncertainty while maintaining the highest standards of patient safety and data quality.
For organizations seeking to strengthen their RBQM capabilities, exploring dedicated RBQM platforms and expert support can be a valuable step toward more proactive, data-driven oversight across the clinical trial lifecycle.
The COVID-19 pandemic fundamentally changed how clinical trials are monitored and managed worldwide. It exposed vulnerabilities in traditional oversight models and accelerated the adoption of risk-based approaches.
Discover how global disruption reshaped clinical trial operations and what the industry learned about managing risk at scale.
Featured Insights
Start Your Roll-Out
RBQM Capability Pathway
Quick Answers
Presented By
Dr. Artem Andrianov
Cyntegrity
Presented By
Shehnaz Vakharia
ADAMAS Consulting
From retrospective QA → to continuous, data-driven oversight
Date
April, 27th 2026
